鱼跃医疗(002223) - 2024 Q1 - 季度财报

Financial Performance - Revenue for the first quarter of 2024 was RMB 2,231,209,294.86, a decrease of 17.44% compared to the same period last year[3] - Net profit attributable to shareholders of the listed company was RMB 659,412,768.43, a decrease of 7.58% year-on-year[3] - Total operating income decreased to 2,231,209,294.86 RMB, down by 17.44% year-over-year[15] - Operating profit for the first quarter of 2024 was RMB 777.03 million, a decrease from RMB 865.19 million in the same period last year[16] - Net profit attributable to the parent company's owners was RMB 659.41 million, compared to RMB 713.52 million in the previous year[16] - The company's total comprehensive income for the quarter was RMB 658.07 million, compared to RMB 708.00 million in the same period last year[16] - Basic earnings per share for the quarter were RMB 0.6619, down from RMB 0.7186 in the same period last year[16] Cash Flow - Net cash flow from operating activities was RMB 675,553,263.28, down 17.14% compared to the same period last year[3] - Cash flow from operating activities was RMB 675.55 million, down from RMB 815.33 million in the prior year[17] - Cash flow from investing activities showed a net outflow of RMB 28.30 million, an improvement from a net outflow of RMB 1.55 billion in the previous year[17] - Cash flow from financing activities had a net outflow of RMB 199.52 million, compared to a net outflow of RMB 370.68 million in the same period last year[18] - Total cash and cash equivalents at the end of the period were RMB 7.64 billion, up from RMB 3.64 billion in the previous year[18] - Net cash flow from investment activities increased by 98.18% year-on-year, mainly due to the company's investment in Chongqing Ant Consumer Finance Co., Ltd. and the purchase of structured deposits in the same period last year[7] Assets and Liabilities - Total assets at the end of the reporting period were RMB 16,599,651,823.63, an increase of 3.96% compared to the end of the previous year[3] - Total assets increased to 16,599,651,823.63 RMB, up by 3.96% compared to the previous period[13] - Total current assets at the end of the period amount to 10,078,070,805.88 RMB, up from 9,385,155,178.47 RMB at the beginning of the period[12] - Long-term receivables at the end of the period are 654,332,861.49 RMB, unchanged from the beginning of the period[12] - Total liabilities decreased to 4,013,294,011.01 RMB, down by 0.95% compared to the previous period[13] - Total equity increased to 12,586,357,812.62 RMB, up by 5.63% compared to the previous period[14] Accounts Receivable and Inventory - Accounts receivable at the end of the reporting period increased by 97.39% compared to the beginning of the period, mainly due to an increase in reasonable receivables within the credit period generated by normal business activities[6] - Accounts receivable at the end of the period amount to 884,734,318.76 RMB, up from 448,210,952.92 RMB at the beginning of the period[12] - Inventory at the end of the period is 1,197,429,569.07 RMB, down from 1,412,311,882.61 RMB at the beginning of the period[12] Income and Expenses - Other income increased by 512.00% year-on-year, mainly due to an increase in government subsidies received during the reporting period[6] - Financial expenses decreased by 4519.01% year-on-year, mainly due to an increase in interest income from bank time deposits and a decrease in loan interest expenses[6] - Cash received from tax refunds increased by 58.14% year-on-year, mainly due to an increase in export tax refunds from export business[6] - Operating costs decreased to 1,584,225,003.71 RMB, down by 14.26% compared to the previous year[15] - R&D expenses decreased to 124,450,232.82 RMB, down by 7.97% year-over-year[15] - Financial expenses showed a net income of 50,842,630.47 RMB, primarily due to higher interest income[15] - Other income increased significantly to 156,252,340.07 RMB, up by 511.89% year-over-year[15] - Credit impairment losses increased to -25,356,963.05 RMB, up by 65.68% compared to the previous year[15] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period is 53,675[8] - Jiangsu Yuyue Technology Development Co., Ltd. holds 24.54% of the shares, totaling 245,983,450 shares[8] - Wu Guangming, an individual shareholder, holds 10.32% of the shares, totaling 103,438,537 shares[8] - Wu Qun, another individual shareholder, holds 7.72% of the shares, totaling 77,389,840 shares, with 58,042,380 shares under restricted sale conditions[8] - Hong Kong Securities Clearing Company Ltd. holds 3.52% of the shares, totaling 35,239,310 shares[8] Monetary Funds and Exchange Rate Impact - The total monetary funds at the end of the period amount to 7,648,128,210.89 RMB, an increase from 7,215,419,322.83 RMB at the beginning of the period[12] - The impact of exchange rate changes on cash and cash equivalents increased by 104.24% year-on-year, mainly due to fluctuations in the US dollar exchange rate during the reporting period[7] Sales and Payments - Sales revenue from goods and services was RMB 2.02 billion, a decrease from RMB 2.66 billion in the previous year[17] - Payments for goods and services were RMB 675.39 million, down from RMB 768.02 million in the prior year[17]